Search Results

You are looking at 11 - 20 of 167 items for :

  • Abstract: Mineral x
  • Abstract: Calcium x
  • Abstract: Hyperparathyroidism x
  • Abstract: Hypoparathyroidism x
  • Abstract: Skeleton x
  • Abstract: Vitamin D x
Clear All Modify Search
A Chinoy Royal Manchester Children’s Hospital, Manchester, UK

Search for other papers by A Chinoy in
Google Scholar
PubMed
Close
,
M Skae Royal Manchester Children’s Hospital, Manchester, UK

Search for other papers by M Skae in
Google Scholar
PubMed
Close
,
A Babiker King Abdullah Specialized Children’s Hospital, Riyadh, Saudi Arabia

Search for other papers by A Babiker in
Google Scholar
PubMed
Close
,
D Kendall Royal Preston Hospital, Preston, UK

Search for other papers by D Kendall in
Google Scholar
PubMed
Close
,
M Z Mughal Royal Manchester Children’s Hospital, Manchester, UK

Search for other papers by M Z Mughal in
Google Scholar
PubMed
Close
, and
R Padidela Royal Manchester Children’s Hospital, Manchester, UK

Search for other papers by R Padidela in
Google Scholar
PubMed
Close

Background

Hypoparathyroidism is characterised by hypocalcaemia, and standard management is with an active vitamin D analogue and adequate oral calcium intake (dietary and/or supplements). Little is described in the literature about the impact of intercurrent illnesses on calcium homeostasis in children with hypoparathyroidism.

Methods

We describe three children with hypoparathyroidism in whom intercurrent illnesses led to hypocalcaemia and escalation of treatment with alfacalcidol (1-hydroxycholecalciferol) and calcium supplements.

Results

Three infants managed with standard treatment for hypoparathyroidism (two with homozygous mutations in GCMB2 gene and one with Sanjad-Sakati syndrome) developed symptomatic hypocalcaemia (two infants developed seizures) following respiratory or gastrointestinal illnesses. Substantial increases in alfacalcidol doses (up to three times their pre-illness doses) and calcium supplementation were required to achieve acceptable serum calcium concentrations. However, following resolution of illness, these children developed an increase in serum calcium and hypercalciuria, necessitating rapid reduction to pre-illness dosages of alfacalcidol and oral calcium supplementation.

Conclusion

Intercurrent illness may precipitate symptomatic hypocalcaemia in children with hypoparathyroidism, necessitating increase in dosages of alfacalcidol and calcium supplements. Close monitoring is required on resolution of the intercurrent illness, with timely reduction of dosages of active analogues of vitamin D and calcium supplements to prevent hypercalcaemia, hypercalciuria and nephrocalcinosis.

Open access
Mirjam M Oosterwerff Departments of Internal Medicine, Epidemiology and Biostatistics, Public and Occupational Health, Endocrine Section

Search for other papers by Mirjam M Oosterwerff in
Google Scholar
PubMed
Close
,
Rosa Meijnen Departments of Internal Medicine, Epidemiology and Biostatistics, Public and Occupational Health, Endocrine Section

Search for other papers by Rosa Meijnen in
Google Scholar
PubMed
Close
,
Natasja M Van Schoor Departments of Internal Medicine, Epidemiology and Biostatistics, Public and Occupational Health, Endocrine Section

Search for other papers by Natasja M Van Schoor in
Google Scholar
PubMed
Close
,
Dirk L Knol Departments of Internal Medicine, Epidemiology and Biostatistics, Public and Occupational Health, Endocrine Section

Search for other papers by Dirk L Knol in
Google Scholar
PubMed
Close
,
Mark H H Kramer Departments of Internal Medicine, Epidemiology and Biostatistics, Public and Occupational Health, Endocrine Section

Search for other papers by Mark H H Kramer in
Google Scholar
PubMed
Close
,
Mireille N M Van Poppel Departments of Internal Medicine, Epidemiology and Biostatistics, Public and Occupational Health, Endocrine Section

Search for other papers by Mireille N M Van Poppel in
Google Scholar
PubMed
Close
,
Paul Lips Departments of Internal Medicine, Epidemiology and Biostatistics, Public and Occupational Health, Endocrine Section

Search for other papers by Paul Lips in
Google Scholar
PubMed
Close
, and
E Marelise W Eekhoff Departments of Internal Medicine, Epidemiology and Biostatistics, Public and Occupational Health, Endocrine Section

Search for other papers by E Marelise W Eekhoff in
Google Scholar
PubMed
Close

Vitamin D deficiency is highly prevalent among non-western immigrants in The Netherlands and associated with poor physical performance. The aim of this study was to assess the effect of vitamin D supplementation on physical performance, exercise capacity, and daily physical activity in vitamin D-deficient, overweight non-western immigrants. A randomized double-blind, placebo-controlled trial was conducted to assess the effect of vitamin D on physical performance. A total of 130 participants were included. Eligibility criteria included overweight (BMI >27 kg/m2), 25-hydroxy vitamin D (25(OH)D) ≤50 nmol/l, and an age range of 20–65 years. The intervention group received 1200 IU vitamin D3 daily for 4 months; the control group received placebo. Both groups received 500 mg calcium daily. Outcome measures included physical performance (physical performance score), exercise capacity (a 6-min walk test (6-MWT)), and daily physical activity (questionnaire and accelerometer). There was no significant effect on physical performance, exercise capacity, or physical activity in the intention to treat analysis. In an explorative post hoc analysis restricted to participants reaching a serum 25(OH)D concentration of >60 nmol/l after intervention, there was an improvement of 19 m in the 6-MWT compared with the control group (P=0.053). Moderate dose vitamin D supplementation did not significantly improve physical performance, exercise capacity, or physical activity. However, when 25(OH)D concentrations reached >60 nmol/l after intervention, there was a borderline significant improvement in exercise capacity. Although the clinical relevance is not clear, this is a promising result, as all participants were overweight and did not improve their overall activity levels.

Open access
Stan Ursem Department of Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Amsterdam, Netherlands

Search for other papers by Stan Ursem in
Google Scholar
PubMed
Close
,
Vito Francic Division of Endocrinology and Diabetology, Department of Internal Medicine, Endocrinology Lab Platform, Medical University of Graz, Graz, Austria

Search for other papers by Vito Francic in
Google Scholar
PubMed
Close
,
Martin Keppel University Institute for Medical and Chemical Laboratory Diagnostics, Paracelsus Medical University, Salzburg, Austria

Search for other papers by Martin Keppel in
Google Scholar
PubMed
Close
,
Verena Schwetz Division of Endocrinology and Diabetology, Department of Internal Medicine, Endocrinology Lab Platform, Medical University of Graz, Graz, Austria

Search for other papers by Verena Schwetz in
Google Scholar
PubMed
Close
,
Christian Trummer Division of Endocrinology and Diabetology, Department of Internal Medicine, Endocrinology Lab Platform, Medical University of Graz, Graz, Austria

Search for other papers by Christian Trummer in
Google Scholar
PubMed
Close
,
Marlene Pandis Division of Endocrinology and Diabetology, Department of Internal Medicine, Endocrinology Lab Platform, Medical University of Graz, Graz, Austria

Search for other papers by Marlene Pandis in
Google Scholar
PubMed
Close
,
Felix Aberer Division of Endocrinology and Diabetology, Department of Internal Medicine, Endocrinology Lab Platform, Medical University of Graz, Graz, Austria

Search for other papers by Felix Aberer in
Google Scholar
PubMed
Close
,
Martin R Grübler Division of Endocrinology and Diabetology, Department of Internal Medicine, Endocrinology Lab Platform, Medical University of Graz, Graz, Austria

Search for other papers by Martin R Grübler in
Google Scholar
PubMed
Close
,
Nicolas D Verheyen Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

Search for other papers by Nicolas D Verheyen in
Google Scholar
PubMed
Close
,
Winfried März Synlab Academy, Synlab Holding Germany GmbH, München, Germany

Search for other papers by Winfried März in
Google Scholar
PubMed
Close
,
Andreas Tomaschitz Specialist Clinic of Rehabilitation Bad Gleichenberg, Bad Gleichenberg, Austria

Search for other papers by Andreas Tomaschitz in
Google Scholar
PubMed
Close
,
Stefan Pilz Division of Endocrinology and Diabetology, Department of Internal Medicine, Endocrinology Lab Platform, Medical University of Graz, Graz, Austria

Search for other papers by Stefan Pilz in
Google Scholar
PubMed
Close
,
Barbara Obermayer-Pietsch Division of Endocrinology and Diabetology, Department of Internal Medicine, Endocrinology Lab Platform, Medical University of Graz, Graz, Austria

Search for other papers by Barbara Obermayer-Pietsch in
Google Scholar
PubMed
Close
, and
Annemieke C Heijboer Department of Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Amsterdam, Netherlands
Department of Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam, Endocrine Laboratory, Amsterdam, Netherlands

Search for other papers by Annemieke C Heijboer in
Google Scholar
PubMed
Close

Objective

PTH can be oxidised in vivo, rendering it biologically inactive. Non-oxidised PTH (n-oxPTH) may therefore give a better image of the hormonal status of the patient. While vitamin D supplementation decreases total PTH (tPTH) concentration, the effect on n-oxPTH concentration is unexplored. We investigated the effect of vitamin D on n-oxPTH concentration in comparison to tPTH and compared the correlations between parameters of calcium, bone and lipid metabolism with n-oxPTH and tPTH.

Methods

N-oxPTH was measured in 108 vitamin D-insufficient (25(OH)D <75 nmol/L) hypertensive patients, treated with vitamin D (2800 IE daily) or placebo for 8 weeks in the Styrian Vitamin D Hypertension Trial (NCT02136771). We calculated the treatment effect and performed correlation analyses of n-oxPTH and tPTH with parameters of calcium, bone and lipid metabolism and oxidative stress.

Results

After treatment, compared to placebo, 25(OH)D concentrations increased, tPTH decreased by 9% (P < 0.001), n-oxPTH by 7% (P = 0.025) and the ratio of n-oxPTH/tPTH increased (P = 0.027). Changes in phosphate and HDL concentration correlated with changes in n-oxPTH, but not tPTH.

Conclusions

tPTH and n-oxPTH decrease upon vitamin D supplementation. Our study suggests that vitamin D supplementation reduces the oxidation of PTH, as we observed a small but significant increase in the non-oxidised proportion of PTH upon treatment. In addition, we found that changes in phosphate and HDL concentration showed a relationship with changes in n-oxPTH, but not tPTH. This may be explained by the biological activity of n-oxPTH. Further research should be carried out to establish the clinical relevance of n-oxPTH.

Open access
Mateo Amaya-Montoya School of Medicine, Universidad de los Andes, Bogotá, Colombia

Search for other papers by Mateo Amaya-Montoya in
Google Scholar
PubMed
Close
,
Daniela Duarte-Montero School of Medicine, Universidad de los Andes, Bogotá, Colombia

Search for other papers by Daniela Duarte-Montero in
Google Scholar
PubMed
Close
,
Luz D Nieves-Barreto School of Medicine, Universidad de los Andes, Bogotá, Colombia

Search for other papers by Luz D Nieves-Barreto in
Google Scholar
PubMed
Close
,
Angélica Montaño-Rodríguez School of Medicine, Universidad de los Andes, Bogotá, Colombia

Search for other papers by Angélica Montaño-Rodríguez in
Google Scholar
PubMed
Close
,
Eddy C Betancourt-Villamizar Team Foods, Bogotá, Colombia

Search for other papers by Eddy C Betancourt-Villamizar in
Google Scholar
PubMed
Close
,
María P Salazar-Ocampo School of Medicine, Universidad de los Andes, Bogotá, Colombia

Search for other papers by María P Salazar-Ocampo in
Google Scholar
PubMed
Close
, and
Carlos O Mendivil School of Medicine, Universidad de los Andes, Bogotá, Colombia
Fundación Santa Fe de Bogotá, Section of Endocrinology, Bogotá, Colombia

Search for other papers by Carlos O Mendivil in
Google Scholar
PubMed
Close

Data on dietary calcium and vitamin D intake from Latin America are scarce. We explored the main correlates and dietary sources of calcium and vitamin D in a probabilistic, population-based sample from Colombia. We studied 1554 participants aged 18–75 from five different geographical regions. Dietary intake was assessed by employing a 157-item semi-quantitative food frequency questionnaire and national and international food composition tables. Daily vitamin D intake decreased with increasing age, from 230 IU/day in the 18–39 age group to 184 IU/day in the 60–75 age group (P -trend < 0.001). Vitamin D intake was positively associated with socioeconomic status (SES) (196 IU/day in lowest vs 234 in highest SES, P-trend < 0.001), and with educational level (176 IU/day in lowest vs 226 in highest education level, P-trend < 0.001). Daily calcium intake also decreased with age, from 1376 mg/day in the 18–39 age group to 1120 mg/day in the 60–75 age group (P -trend < 0.001). Calcium intake was lowest among participants with only elementary education, but the absolute difference in calcium intake between extreme education categories was smaller than for vitamin D (1107 vs 1274 mg/day, P-trend = 0.023). Daily calcium intake did not correlate with SES (P -trend = 0.74). Eggs were the main source of overall vitamin D, albeit their contribution decreased with increasing age. Dairy products contributed at least 48% of dietary calcium in all subgroups, mostly from cheese-containing traditional foods. SES and education were the key correlates of vitamin D and calcium intake. These findings may contribute to shape public health interventions in Latin American countries.

Open access
Niek F Dirks Atalmedial Diagnostics Centre, Spaarne Gasthuis, Haarlem, The Netherlands
Department of Clinical Chemistry, Hematology and Immunology, Noordwest Ziekenhuis, Alkmaar, The Netherlands

Search for other papers by Niek F Dirks in
Google Scholar
PubMed
Close
,
Etienne Cavalier Department of Clinical Chemistry, University of Liège, CHU de Liège, Liège, Belgium

Search for other papers by Etienne Cavalier in
Google Scholar
PubMed
Close
, and
Annemieke C Heijboer Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Clinical Chemistry, Endocrine Laboratory, Boelelaan, Amsterdam, The Netherlands
Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands
Amsterdam UMC location University of Amsterdam, Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam, The Netherlands
Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands

Search for other papers by Annemieke C Heijboer in
Google Scholar
PubMed
Close

The measurement of vitamin D metabolites aids in assessing vitamin D status and in diagnosing disorders of calcium homeostasis. Most laboratories measure total 25-hydroxyvitamin D (25(OH)D), while others have taken the extra effort to measure 25(OH)D2 and 25(OH)D3 separately and additional metabolites such as 1,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D. The aim of this review is to provide an updated overview of the main markers of vitamin D metabolism, define the intended measurands, and discuss the advantages and disadvantages of the two most widely used assays, automated assays and liquid chromatography–tandem mass spectrometry (LC-MS/MS). Whether using the easy and fast automated assays or the more complex LC-MS/MS, one should know the pitfalls of the used technique in order to interpret the measurements. In conclusion, automated assays are unable to accurately measure 25(OH)D in all patient groups, including persons using D2. In these cases, an LC-MS/MS method, when appropriately developed and standardized, produces a more reliable measurement.

Open access
Laura P B Elbers Department of Internal Medicine, Medical Center Slotervaart, Amsterdam, the Netherlands
Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

Search for other papers by Laura P B Elbers in
Google Scholar
PubMed
Close
,
Marije Wijnberge Department of Internal Medicine, Medical Center Slotervaart, Amsterdam, the Netherlands
Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Laboratory of Experimental Intensive Care and Anesthesiology, Academic Medical Center, University of Amsterdam, the Netherlands

Search for other papers by Marije Wijnberge in
Google Scholar
PubMed
Close
,
Joost C M Meijers Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Department of Plasma Proteins, Sanquin Research, Amsterdam, the Netherlands

Search for other papers by Joost C M Meijers in
Google Scholar
PubMed
Close
,
Dennis C W Poland Clinical Chemistry Laboratory, Medical Center Slotervaart, Amsterdam, the Netherlands

Search for other papers by Dennis C W Poland in
Google Scholar
PubMed
Close
,
Dees P M Brandjes Department of Internal Medicine, Medical Center Slotervaart, Amsterdam, the Netherlands
Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

Search for other papers by Dees P M Brandjes in
Google Scholar
PubMed
Close
,
Eric Fliers Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

Search for other papers by Eric Fliers in
Google Scholar
PubMed
Close
, and
Victor E A Gerdes Department of Internal Medicine, Medical Center Slotervaart, Amsterdam, the Netherlands
Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

Search for other papers by Victor E A Gerdes in
Google Scholar
PubMed
Close

Introduction

Abnormal coagulation tests have been observed in patients with primary hyperparathyroidism (HPT) suggesting a prothrombotic effect of parathyroid hormone (PTH). Vitamin D deficiency (VIDD) is the most frequent cause of secondary HPT. Aim of our study was to investigate the influence of HPT secondary to moderate-to-severe VIDD and vitamin D replacement on the coagulation and fibrinolysis system.

Subjects and methods

Prospective cohort study of patients with vitamin D <25 nmol/L with and without HPT, and a control group of patients on vitamin D suppletion. At baseline and after 2 months of vitamin D suppletion (900,000 IU in 2 months), endocrine and coagulation markers were measured.

Results

59 patients with VIDD of which 34 had secondary HPT and 36 controls were included. After 2 months of suppletion, vitamin D increased by 399% (VIDD with HPT), 442% (all patients with VIDD) and 6% (controls). PTH decreased by 34% (VIDD with HPT, P < 0.01 for decrease), 32% (all VIDD, P < 0.01) and increased by 8% in the controls (P-values: <0.01 for relative changes between VIDD with HPT or all VIDD patients vs controls). Relative changes in PT, aPTT, fibrinogen, Von Willebrand factor, factors VII, VIII and X, thrombin generation, TAFI, clot-lysis time and d-dimer were not different between patients with VIDD with HPT or all VIDD vs controls.

Discussion

Secondary HPT due to VIDD does not have a prothrombotic effect. In contrast with previous reports, PTH does not seem to influence coagulation or fibrinolysis, which is relevant because of the high prevalence of VIDD.

Open access
Melissa Braga Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California, USA

Search for other papers by Melissa Braga in
Google Scholar
PubMed
Close
,
Zena Simmons Department of Health & Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, California, USA

Search for other papers by Zena Simmons in
Google Scholar
PubMed
Close
,
Keith C Norris Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA

Search for other papers by Keith C Norris in
Google Scholar
PubMed
Close
,
Monica G Ferrini Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California, USA
Department of Health & Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, California, USA
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA

Search for other papers by Monica G Ferrini in
Google Scholar
PubMed
Close
, and
Jorge N Artaza Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California, USA
Department of Health & Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, California, USA
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA

Search for other papers by Jorge N Artaza in
Google Scholar
PubMed
Close

Skeletal muscle wasting is a serious disorder associated with health conditions such as aging, chronic kidney disease and AIDS. Vitamin D is most widely recognized for its regulation of calcium and phosphate homeostasis in relation to bone development and maintenance. Recently, vitamin D supplementation has been shown to improve muscle performance and reduce the risk of falls in vitamin D deficient older adults. However, little is known of the underlying molecular mechanism(s) or the role it plays in myogenic differentiation. We examined the effect of 1,25-D3 on myogenic cell differentiation in skeletal muscle derived stem cells. Primary cultures of skeletal muscle satellite cells were isolated from the tibialis anterior, soleus and gastrocnemius muscles of 8-week-old C57/BL6 male mice and then treated with 1,25-D3. The efficiency of satellite cells isolation determined by PAX7+ cells was 81%, and they expressed VDR. Incubation of satellite cells with 1,25-D3 induces increased expression of: (i) MYOD, (ii) MYOG, (iii) MYC2, (iv) skeletal muscle fast troponin I and T, (v) MYH1, (vi) IGF1 and 2, (vii) FGF1 and 2, (viii) BMP4, (ix) MMP9 and (x) FST. It also promotes myotube formation and decreases the expression of MSTN. In conclusion, 1,25-D3 promoted a robust myogenic effect on satellite cells responsible for the regeneration of muscle after injury or muscle waste. This study provides a mechanistic justification for vitamin D supplementation in conditions characterized by loss of muscle mass and also in vitamin D deficient older adults with reduced muscle mass and strength, and increased risk of falls.

Open access
Guido Zavatta Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

Search for other papers by Guido Zavatta in
Google Scholar
PubMed
Close
and
Bart L Clarke Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Bart L Clarke in
Google Scholar
PubMed
Close

The first adjunctive hormone therapy for chronic hypoparathyroidism, recombinant human parathyroid hormone (1–84) (rhPTH(1–84)) was approved by the FDA in January 2015. Since the approval of rhPTH(1–84), growing interest has developed in other agents to treat this disorder in both the scientific community and among pharmaceutical companies. For several reasons, conventional therapy with calcium and activated vitamin D supplementation, magnesium supplementation as needed, and occasionally thiazide-type diuretic therapy remains the mainstay of treatment, while endocrinologists and patients are constantly challenged by limitations of conventional treatment. Serum calcium fluctuations, increased urinary calcium, hyperphosphatemia, and a constellation of symptoms that limit mental and physical functioning are frequently associated with conventional therapy. Understanding how conventional treatment and hormone therapy work in terms of pharmacokinetics and pharmacodynamics is key to effectively managing chronic hypoparathyroidism. Multiple questions remain regarding the effectiveness of PTH adjunctive therapy in preventing or slowing the onset and progression of the classical complications of hypoparathyroidism, such as chronic kidney disease, calcium-containing kidney stones, cataracts, or basal ganglia calcification. Several studies point toward an improvement in the quality of life during replacement therapy. This review will discuss current clinical and research challenges posed by treatment of chronic hypoparathyroidism.

Key points:

  • Conventional therapy with calcium and activated forms of vitamin D are currently the mainstays of treatment for most patients with chronic hypoparathyroidism.

  • Hormone therapy can be administered through FDA-approved once-daily rhPTH(1–84), or off-label multiple-daily injections of teriparatide. The former is the only FDA-approved drug, with safety and efficacy supported by a randomized placebo-controlled trial and open-label long-term extension trial data.

  • Twice-daily teriparatide has been used in children safely for up to 10 years.

  • New pharmacological options that replace the deficient hormone wi ll likely be available within the next few years.

Open access
Malachi J McKenna Metabolism Laboratory, Department of Endocrinology, School of Medicine and Medical Sciences, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland
Metabolism Laboratory, Department of Endocrinology, School of Medicine and Medical Sciences, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland
Metabolism Laboratory, Department of Endocrinology, School of Medicine and Medical Sciences, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland

Search for other papers by Malachi J McKenna in
Google Scholar
PubMed
Close
,
Barbara F Murray Metabolism Laboratory, Department of Endocrinology, School of Medicine and Medical Sciences, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland

Search for other papers by Barbara F Murray in
Google Scholar
PubMed
Close
,
Myra O'Keane Metabolism Laboratory, Department of Endocrinology, School of Medicine and Medical Sciences, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland

Search for other papers by Myra O'Keane in
Google Scholar
PubMed
Close
, and
Mark T Kilbane Metabolism Laboratory, Department of Endocrinology, School of Medicine and Medical Sciences, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland

Search for other papers by Mark T Kilbane in
Google Scholar
PubMed
Close

Background

The Institute of Medicine 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D specified higher intakes for all age groups compared to the 1997 report, but also cautioned against spurious claims about an epidemic of vitamin D deficiency and against advocates of higher intake requirements. Over 40 years, we have noted marked improvement in vitamin D status but we are concerned about hypervitaminosis D.

Objective

We sought to evaluate the 25-hydroxyvitamin D (25OHD) trend over 20 years.

Design

We retrieved all results of serum 25OHD from 1993 to 2013 (n=69 012) that was trimmed to one sample per person (n=43 782). We conducted a time series analysis of the monthly averages for 25OHD using a simple sequence chart and a running median smoothing function. We modelled the data using univariate auto-regressive integrated moving average (ARIMA) and forecast 25OHD levels up to 2016.

Results

The time series sequence chart and smoother function demonstrated a steady upward trend with seasonality. The yearly average 25OHD increased from 36.1 nmol/l in 1993 to 57.3 nmol/l in 2013. The ARIMA model was a good fit for the 25OHD time series; it forecasted monthly average 25OHD up to the end of 2016 with a positive stationary R 2 of 0.377.

Conclusions

Vitamin D status improved over the past 40 years, but there remains a dual problem: there are groups at risk of vitamin D deficiency who need public health preventative measures; on the other hand, random members of the population are taking unnecessarily high vitamin D intakes for unsubstantiated claims.

Open access
Xiaoli Jin Department of General Surgery, Ruijin Hospital Lu Wan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China

Search for other papers by Xiaoli Jin in
Google Scholar
PubMed
Close
,
Jiankang Shen Department of General Surgery, Ruijin Hospital Lu Wan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China

Search for other papers by Jiankang Shen in
Google Scholar
PubMed
Close
,
Tao Liu Department of General Surgery, Ruijin Hospital Lu Wan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China

Search for other papers by Tao Liu in
Google Scholar
PubMed
Close
,
Ru Zhou Department of General Surgery, Ruijin Hospital Lu Wan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China

Search for other papers by Ru Zhou in
Google Scholar
PubMed
Close
,
Xunbo Huang Department of General Surgery, Ruijin Hospital Lu Wan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China

Search for other papers by Xunbo Huang in
Google Scholar
PubMed
Close
,
Tianxiang Wang Department of General Surgery, Ruijin Hospital Lu Wan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Tianxiang Wang in
Google Scholar
PubMed
Close
,
Weize Wu Department of General Surgery, Ruijin Hospital Lu Wan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Weize Wu in
Google Scholar
PubMed
Close
,
Mingliang Wang Department of General Surgery, Ruijin Hospital Lu Wan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Mingliang Wang in
Google Scholar
PubMed
Close
,
Rongli Xie Department of General Surgery, Ruijin Hospital Lu Wan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China

Search for other papers by Rongli Xie in
Google Scholar
PubMed
Close
, and
Jianming Yuan Department of General Surgery, Ruijin Hospital Lu Wan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China

Search for other papers by Jianming Yuan in
Google Scholar
PubMed
Close

Objective

The aim was to explore the effects of preoperative calcium and activated vitamin D3 supplementation on post-thyroidectomy hypocalcemia and hypo-parathyroid hormone-emia (hypo-PTHemia).

Methods

A total of 209 patients were randomly divided into control group (CG) and experimental group (EG). Oral calcium and activated vitamin D3 supplementation were preoperatively administered to EG, whereas a placebo was administered to CG. Data on serum calcium, phosphorus, and PTH concentrations before operation, on postoperative day 1 (POPD1), at postoperative week 3 (POPW3), and on the length of postoperative hospitalization were collected.

Results

The serum calcium, phosphorus, and PTH concentrations, as well as the incidence of postoperative hypocalcemia and hypo-PTHemia, did not significantly differ between EG and CG. Subgroup analysis revealed that the serum calcium concentrations of the experimental bilateral thyroidectomy subgroup (eBTS) on POPD1 and POPW3 were higher than that of the control bilateral thyroidectomy subgroup (cBTS) (P < 0.05); the reduction of serum calcium in eBTS on POPD1 and POPW3 was less than those in cBTS (P < 0.05). However, significant differences were not observed between the unilateral thyroidectomy subgroups (UTS) (P > 0.05). Moreover, the incidence of postoperative hypocalcemia in cBTS on POPD1 was significantly higher than that in eBTS (65.9% vs 41.7%) (P < 0.05). The length of hospitalization in cBTS (3.55 ± 1.89 days) was significantly longer than that (2.79 ± 1.15 days) in eBTS (P < 0.05).

Conclusion

Short-term preoperative prophylactic oral calcium and activated vitamin D3 supplementation could effectively reduce the incidence of postoperative hypocalcemia and decrease the length of postoperative hospitalization in patients who have undergone bilateral thyroidectomy.

Open access